www.bioscience.co.uk
Sales & Support: +44 (0)1223 316 855

*

Properdin, Human, mAb 1G6D2

Catalogue number:
HM2354-100UG
Supplier:
Size:
100 µg _$$_
Product is available in:
  • UK
  • Ireland
  • Europe
  • USA
  • Rest of World
£410.00 Shipping is calculated in checkout
Applications:

Functional studies, Immuno assays, Western blot

Immunogen:

Human properdin purified from human plasma.

Product Description:

Monoclonal antibody 1G6D2 recognizes human properdin, also called complement factor P. The complement system is the first line of defense against pathogens and facilitates elimination of apoptotic and damaged cells. Positive regulator plasma protein properdin is critical for the alternative pathway of complement. It is a single-chain glycoprotein (ca 53kDa) consisting of six TSR sequences. In the blood it exists as a mixture of preferably head-to-tail trimers, but also dimers and tetramers. The protein is produced by leukocytes, like activated neutrophils monocytes and T-lymphocytes, but also by eg. stressed endothelial cells.Properdin can both initiate and positively regulate the alternative pathway activity together with C3 and factors B, D, I and H. It binds to C3b where It stabilizes the labile C3bBb convertase which is deposited on immune complexes or foreign surfaces. Thereby enhancing the AP by stimulation of amplification of C3bBb-convertase formation in competition with catabolism of C3b by factor I, which uses factor H as a cofactor. The local amplification process leads to the creation of the alternative pathway C5 convertase, C3bBb3b, and initiates the terminal pathway of complement activation. The alternative pathway may account for ca 80% of the terminal pathway activity. Properdin has also been shown to directly limit factor H activity.Recent studies show that properdin is also a pattern-recognition receptor (PRR) able to bind directly to microbial surfaces, apoptotic and necrotic cells (dangerous nonself and altered self). Inappropriate activation or dysregulation of the alternative pathway is a critical factor in development of several autoimmune conditions. Targets opsonized with properdin are labeled for clearance by scavenger cells, even without complement. This makes it a potential therapeutic target in diseases. Recent studies has shown renewed interest in the evaluating role of properdin in disease pathogenesis, like Asthma, arthritis, septic shock, AMD and C3 glomerulopathy.Antibody 1G6D2 can be used in ELISA, western blotting (only non-reduced) and as negative control antibody for functional studies inhibiting the alternative pathway of complement (Ref 1).

Details Cat number & supplier Size Price
C5, Mouse, mAb BB5.1 HM1073-100MG · Hycult Biotech
HM1073-100MG
Hycult Biotech
100 mg £43847.00
100 mg
view
Activated C3, Human, mAb I3/15 HM2257-100UG · Hycult Biotech
HM2257-100UG
Hycult Biotech
100 µg £316.00
100 µg
view
C5/C5a, Human, mAb 561 HM2076-100UG · Hycult Biotech
HM2076-100UG
Hycult Biotech
100 µg £410.00
100 µg
view
C3/C3a, Human, mAb 2898 HM2075-100UG · Hycult Biotech
HM2075-100UG
Hycult Biotech
100 µg £410.00
100 µg
view
C3a/C3a des Arg, Human, mAb 2991 HM2074-100UG · Hycult Biotech
HM2074-100UG
Hycult Biotech
100 µg £410.00
100 µg
view
C3c, Human, mAb F1-4 HM2318-100UG · Hycult Biotech
HM2318-100UG
Hycult Biotech
100 µg £452.00
100 µg
view
C3b/iC3b, Human, mAb 3E7 HM2286-100UG · Hycult Biotech
HM2286-100UG
Hycult Biotech
100 µg £505.00
100 µg
view
C3b/iC3b, Human, mAb 5G9 HM2285-100UG · Hycult Biotech
HM2285-100UG
Hycult Biotech
100 µg £505.00
100 µg
view
C9 neoantigen, Human, mAb WU13-15 HM2264-100UG · Hycult Biotech
HM2264-100UG
Hycult Biotech
100 µg £452.00
100 µg
view
C4d, Human, mAb 7H4 HM2230-100UG · Hycult Biotech
HM2230-100UG
Hycult Biotech
100 µg £452.00
100 µg
view